Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Works (33)

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Nature Cancer
2024-08-26 | Journal article
DOI: 10.1038/s43018-024-00818-w
Contributors: Shambavi Richard; Alexander M. Lesokhin; Barry Paul; Jonathan L. Kaufman; Matthew Pianko; Noa Biran; Ravi Vij; Deon B. Doxie; Maryam I. Azeem; Mercedes Martillo et al.
Source: check_circle
Crossref

Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.c.6908301.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.c.6908301
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S1 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473959.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S1 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473959
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473956
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473956.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473559.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473559
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473953.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473953
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473556
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473556.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473950.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473950
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473553
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473553.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473947
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473947.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473550
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473550.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Blood Cancer Discovery
2023-11-01 | Journal article
DOI: 10.1158/2643-3230.BCD-23-0049
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473944
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473944.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473547
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473547.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473941
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473941.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473544
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023-11-01 | Preprint
DOI: 10.1158/2643-3230.24473544.v1
Contributors: Guido Lancman; Kian Parsa; Krzysztof Kotlarz; Lisa Avery; Alaina Lurie; Alex Lieberman-Cribbin; Hearn Jay Cho; Samir S. Parekh; Shambavi Richard; Joshua Richter et al.
Source: check_circle
Crossref

Trial designs and endpoints for immune therapies in multiple myeloma

American Journal of Hematology
2023-03 | Journal article
DOI: 10.1002/ajh.26753
Contributors: Guido Lancman; Erin Moshier; Hearn Jay Cho; Samir Parekh; Shambavi Richard; Joshua Richter; Cesar Rodriguez; Adriana Rossi; Larysa Sanchez; Sundar Jagannath et al.
Source: check_circle
Crossref

A three gene signature predicts response to selinexor in multiple myeloma

2022-02-26 | Preprint
DOI: 10.1101/2022.02.25.22271401
Contributors: Paula Restrepo; Sherry Bhalla; Adolfo Aleman; Violetta Leshchenko; David T Melnekoff; Sarita Agte; Joy Jiang; Deepu Madduri; Joshua Richter; Shambavi Richard et al.
Source: check_circle
Crossref

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

American Journal of Hematology
2021-09 | Journal article
DOI: 10.1002/ajh.26261
Contributors: Shambavi Richard; Ajai Chari; Sosana Delimpasi; Maryana Simonova; Ivan Spicka; Ludek Pour; Iryna Kriachok; Meletios A. Dimopoulos; Halyna Pylypenko; Holger W. Auner et al.
Source: check_circle
Crossref
How many people are using ORCID?